FandofloxacinAlternative Names: DW 116
Latest Information Update: 07 Feb 2008
At a glance
- Originator Dong Wha
- Developer Dong Wha Pharmaceutical
- Class Antibacterials; Fluoroquinolones; Piperazines; Quinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Urinary tract infections